DCLK1 Promotes Colorectal Cancer Stemness and Aggressiveness Via the XRCC5/COX2 Axis

Overview

Journal Theranostics

Date 2022 Aug 1

PMID 35910805

Authors

Jee-Heun Kim

So-Yeon Park

So-El Jeon

Jang-Hyun Choi

Choong-Jae Lee

Tae-Young Jang

Hyeon-Ji Yun

Yuno Lee

Pilho Kim

Sang Hee Cho

Ji Shin Lee

Jeong-Seok Nam

Affiliations

Soon will be listed here.

Abstract

Doublecortin-like kinase 1 (DCLK1) is a serine/threonine kinase that selectively marks cancer stem-like cells (CSCs) and promotes malignant progression in colorectal cancer (CRC). However, the exact molecular mechanism by which DCLK1 drives the aggressive phenotype of cancer cells is incompletely determined. Here, we performed comprehensive genomics and proteomics analyses to identify binding proteins of DCLK1 and discovered X-ray repair cross-complementing 5 (XRCC5). Thus, we explored the biological role and downstream events of the DCLK1/XRCC5 axis in human CRC cells and CRC mouse models. The results of comprehensive bioinformatics analyses suggested that DCLK1-driven CRC aggressiveness is linked to inflammation. Mechanistically, DCLK1 bound and phosphorylated XRCC5, which in turn transcriptionally activated cyclooxygenase-2 expression and enhanced prostaglandin E production; these events collectively generated the inflammatory tumor microenvironment and enhanced the aggressive behavior of CRC cells. Consistent with the discovered mechanism, inhibition of DCLK1 kinase activity strongly impaired the tumor seeding and growth capabilities in CRC mouse models. Our study illuminates a novel mechanism that mediates the pro-inflammatory function of CSCs in driving the aggressive phenotype of CRC, broadening the biological function of DCLK1 in CRC.

Citing Articles

Biomimetic Nano-delivery of Small-Molecule Piceatannol Modulates Tumor Stemness and Suppresses Colorectal Cancer Metastasis via Hippo/YAP1/SOX9 Signaling.

Zhou M, Niu H, Huang G, Zhou M, Cui D, Li H Small. 2024; 21(2):e2407191.

PMID: 39523731 PMC: 11735875. DOI: 10.1002/smll.202407191.

From Inflammation to Oncogenesis: Tracing Serum DCLK1 and miRNA Signatures in Chronic Liver Diseases.

Moore L, Qu D, Sureban S, Mitchell S, Pitts K, Cooper N Int J Mol Sci. 2024; 25(12).

PMID: 38928187 PMC: 11203803. DOI: 10.3390/ijms25126481.

Colonic Tuft Cells: The Less-Recognized Therapeutic Targets in Inflammatory Bowel Disease and Colorectal Cancer.

Sipos F, Muzes G Int J Mol Sci. 2024; 25(11).

PMID: 38892399 PMC: 11172904. DOI: 10.3390/ijms25116209.

Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs.

Zhao Q, Zong H, Zhu P, Su C, Tang W, Chen Z Exp Hematol Oncol. 2024; 13(1):6.

PMID: 38254219 PMC: 10802076. DOI: 10.1186/s40164-024-00474-x.

Correlation Between DCAMKL-1 Protein Expression and K-ras Gene Mutation in Colorectal Cancer.

Wu X, Li S, Yang Y, Hu J, Yang T Cancer Manag Res. 2024; 16:11-21.

PMID: 38196736 PMC: 10775797. DOI: 10.2147/CMAR.S440845.

References

Ferguson F, Nabet B, Raghavan S, Liu Y, Leggett A, Kuljanin M . Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020; 16(6):635-643. PMC: 7246176. DOI: 10.1038/s41589-020-0506-0. View

Jin H, Lee B, Luo Y, Choi Y, Choi E, Jin H . FOXL2 directs DNA double-strand break repair pathways by differentially interacting with Ku. Nat Commun. 2020; 11(1):2010. PMC: 7181608. DOI: 10.1038/s41467-020-15748-1. View

Sureban S, May R, Weygant N, Qu D, Chandrakesan P, Bannerman-Menson E . XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer Lett. 2014; 351(1):151-61. DOI: 10.1016/j.canlet.2014.05.011. View

Dennis Jr G, Sherman B, Hosack D, Yang J, Gao W, Lane H . DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003; 4(5):P3. View

Muller L, Tunger A, Plesca I, Wehner R, Temme A, Westphal D . Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets. Front Immunol. 2020; 11:140. PMC: 7013084. DOI: 10.3389/fimmu.2020.00140. View

Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y . Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021; 6(1):263. PMC: 8273155. DOI: 10.1038/s41392-021-00658-5. View

Lei M, Lee T . Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers. Front Cell Dev Biol. 2021; 9:692940. PMC: 8257022. DOI: 10.3389/fcell.2021.692940. View

Wang D, DuBois R . The Role of Prostaglandin E(2) in Tumor-Associated Immunosuppression. Trends Mol Med. 2015; 22(1):1-3. PMC: 4762482. DOI: 10.1016/j.molmed.2015.11.003. View

Mizuno R, Kawada K, Sakai Y . Prostaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer. Int J Mol Sci. 2019; 20(24). PMC: 6940958. DOI: 10.3390/ijms20246254. View

10.

Valenti G, Quinn H, Heynen G, Lan L, Holland J, Vogel R . Cancer Stem Cells Regulate Cancer-Associated Fibroblasts via Activation of Hedgehog Signaling in Mammary Gland Tumors. Cancer Res. 2017; 77(8):2134-2147. DOI: 10.1158/0008-5472.CAN-15-3490. View

11.

Sarkar S, Popov V, OConnell M, Stevenson H, Lee B, Obeid R . A novel antibody against cancer stem cell biomarker, DCLK1-S, is potentially useful for assessing colon cancer risk after screening colonoscopy. Lab Invest. 2017; 97(10):1245-1261. PMC: 5623180. DOI: 10.1038/labinvest.2017.40. View

12.

Weygant N, Qu D, Berry W, May R, Chandrakesan P, Owen D . Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Mol Cancer. 2014; 13:103. PMC: 4030036. DOI: 10.1186/1476-4598-13-103. View

13.

Ge Y, Weygant N, Qu D, May R, Berry W, Yao J . Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer. 2018; 143(5):1162-1175. PMC: 8386112. DOI: 10.1002/ijc.31400. View

14.

Majumder M, Xin X, Liu L, Girish G, Lala P . Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. Cancer Sci. 2014; 105(9):1142-51. PMC: 4462388. DOI: 10.1111/cas.12475. View

15.

Rajput S, Wilber A . Roles of inflammation in cancer initiation, progression, and metastasis. Front Biosci (Schol Ed). 2009; 2(1):176-83. DOI: 10.2741/s55. View

16.

Chen Z, Cole P . Synthetic approaches to protein phosphorylation. Curr Opin Chem Biol. 2015; 28:115-22. PMC: 4624483. DOI: 10.1016/j.cbpa.2015.07.001. View

17.

Zhou H, Zhang J, Zhang X, Li Q . Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Ther. 2021; 6(1):62. PMC: 7884707. DOI: 10.1038/s41392-020-00430-1. View

18.

Lai T, Qiu H, Si L, Zhen Y, Chu D, Guo R . Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway. Cell Cycle. 2022; 21(15):1599-1618. PMC: 9291686. DOI: 10.1080/15384101.2022.2060003. View

19.

Vedeld H, Skotheim R, Lothe R, Lind G . The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer. Epigenetics. 2014; 9(3):346-50. PMC: 4053453. DOI: 10.4161/epi.27582. View

20.

Patel O, Roy M, Kropp A, Hardy J, Dai W, Lucet I . Structural basis for small molecule targeting of Doublecortin Like Kinase 1 with DCLK1-IN-1. Commun Biol. 2021; 4(1):1105. PMC: 8452690. DOI: 10.1038/s42003-021-02631-y. View